Patents by Inventor Laura Martinson

Laura Martinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925488
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: March 12, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Patent number: 11896622
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 13, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Publication number: 20230293812
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 21, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Publication number: 20230256137
    Abstract: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.
    Type: Application
    Filed: April 25, 2023
    Publication date: August 17, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
  • Publication number: 20230233739
    Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.
    Type: Application
    Filed: March 2, 2023
    Publication date: July 27, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Patent number: 11660377
    Abstract: The present invention relates to a cryopreserved in vitro cell culture comprising human pancreatic progenitor cells that co-express pancreatic-duodenal homeobox factor-1 (PDX1) and NK6 homeobox 1 (NKX6.1) and are chromogranin negative. The present invention also relates to a method for cryopreserving an in vitro population of human pancreatic progenitor cells that co-express PDX1 and NKX6.1 and are chromogranin negative.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 30, 2023
    Assignee: ViaCyte, Inc.
    Inventors: Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
  • Patent number: 11642455
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: May 9, 2023
    Assignee: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Patent number: 11623023
    Abstract: Disclosed are devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. The devices include a non-woven fabric external to a cell-excluding membrane, and the non-woven fabric and/or cell-excluding membrane can be perforated. Treatment of the host with immunosuppressive reagents, required to inhibit allograft rejection due to perforations in the cell delivery device, does not compromise maturation or function of transplanted pancreatic endoderm cells.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: April 11, 2023
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Publication number: 20220370184
    Abstract: A biocompatible membrane composite including a cell impermeable layer and a mitigation layer is provided. The cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.
    Type: Application
    Filed: May 30, 2020
    Publication date: November 24, 2022
    Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Craig McGreevy, Laura Martinson, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
  • Publication number: 20220233298
    Abstract: A biocompatible membrane composite that can provide an environment that is able to mitigate or tailor the foreign body response is provided. The membrane composite contains a mitigation layer and a vascularization layer. A reinforcing component may optionally be included to provide support to and prevent distortion of the biocompatible membrane composite in vivo. The mitigation layer may be bonded (e.g., point bonded or welded) or adhered (intimately or discretely) to an implantable device and/or cell system. The biocompatible membrane composite may be used as a surface layer for implantable devices or cell systems that require vascularization for function but need protection from the host's immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite may partially or fully cover the exterior of an implantable device or cell system. The mitigation layer is positioned between the implantable device or bioactive scaffold and the vascularization layer.
    Type: Application
    Filed: May 30, 2020
    Publication date: July 28, 2022
    Inventors: Bahman Aghdasi, Timothy M. Bruhn, Kevin D'Amour, Edward Gunzel, Laura Martinson, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Christopher Folk, Craig McGreevy, Joseph Kakkassery
  • Publication number: 20220233299
    Abstract: Cell encapsulation devices for biological entities and/or cell populations that contain at least one biocompatible membrane composite are provided. The cell encapsulation devices mitigate or tailor the foreign body response from a host such that sufficient blood vessels are able to form at a cell impermeable surface. Additionally, the encapsulation devices have an oxygen diffusion distance that is sufficient for the survival of the encapsulated cells so that the cells are able to secrete a therapeutically useful substance. The biocompatible membrane composite is formed of a cell impermeable layer and a mitigation layer. The cell encapsulation device maintains an optimal oxygen diffusion distance through the design of the cell encapsulation device or through the use of lumen control mechanisms. Lumen control mechanisms include a reinforcing component that is also a nutrient impermeable layer, internal structural pillars, internal tensioning member(s), and/or an internal cell displacing core.
    Type: Application
    Filed: May 30, 2020
    Publication date: July 28, 2022
    Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Edward Gunzel, Evert Kroon, Laura Martinson, Craig McGreevy, Scott Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
  • Publication number: 20220234006
    Abstract: A biocompatible membrane composite including a first layer (cell impermeable layer), a second layer (a mitigation layer), and a third layer (a vascularization layer) is provided. The mitigation layer may be positioned between the cell impermeable layer and the vascularization layer In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned on either side of the biocompatible membrane composite or within the biocompatible membrane composite to provide support to and prevent distortion of the membrane composite. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.
    Type: Application
    Filed: May 30, 2020
    Publication date: July 28, 2022
    Inventors: Timothy M. Bruhn, Kevin D'Amour, Christopher Folk, Evert Kroon, Laura Martinson, Craig McGreevy, Scott A. Ritrovato, Greg Rusch, Michael Scott, Lauren R. Zambotti, Qiang (John) Zhang, Joseph Kakkassery
  • Publication number: 20220105264
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 7, 2022
    Applicant: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Patent number: 11246979
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: February 15, 2022
    Assignee: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Publication number: 20220016406
    Abstract: Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 20, 2022
    Applicant: ViaCyte, Inc.
    Inventors: Vincent So, Laura Martinson, Chad Green, Michael Scott, Mario Zamarripa
  • Publication number: 20210330414
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicant: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Patent number: 11077289
    Abstract: Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: August 3, 2021
    Assignee: ViaCyte, Inc.
    Inventors: Vincent So, Laura Martinson, Chad Green, Michael Scott, Mario Zamarripa
  • Patent number: 11051900
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: July 6, 2021
    Assignee: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Publication number: 20200324043
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Applicant: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Publication number: 20200316135
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Application
    Filed: November 8, 2019
    Publication date: October 8, 2020
    Applicant: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge